-
Japan protests Putin's first visit to disputed islands
-
Hasan takes 6-55 as Bangladesh bundle out Australia for 198
-
Kiss wants fit-again Wallabies playmaker Gordon to 'open up' Japan
-
Swiatek sinks Svitolina to set up Rybakina title clash in Toronto
-
British eccentrics push humble garden shed to new heights
-
Australia's Pallister shines, mixed relay record falls as Pan Pacs open
-
Zambia votes with president's economic record on the line
-
Hasan puts Bangladesh in charge as Australia struggle to 183-8
-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
-
All Blacks' Proctor out of South Africa series, Mo'unga called up
-
Jones says Japan 'watching videos of geese' for Australia clash
-
Bangladesh quick Hasan reduces Australia to 74-4 at lunch
-
Bloodied but unbowed, defending champ Shelton reaches Montreal final
-
Seoul tech leads Asian stock gains as traders cheer US inflation
-
Wallabies make eight changes for return Japan Test
-
Farage and Count Binface go head-to-head in snap UK poll
-
Messi returns after father's death but Miami knocked out of Leagues Cup
-
Afghan students divided over smartphone ban at universities
-
Outflanked by AI, stars fade for South Korea's blind fortune-tellers
-
Japan go back to school for second Australia Test
-
Venezuela govt, opposition wrap up round of post-Maduro talks
-
Matthew McConaughey on his sweet return to the big screen
-
Five things to know about Zambia as it goes to the polls
-
President's economic record on the line as Zambia votes
-
Nakashima holds off Jodar to book first ATP Masters final in Montreal
-
Battery X Metals Appoints Lithium-Ion Battery and Electric Vehicle Entrepreneur William Fan as President to Advance Development of Its Patent-Pending Lithium-Ion Battery Rebalancing Technology Platform and Corporate Growth Initiatives
-
Battery X Metals Maintains Y Lithium Project Claims in Good Standing and Evaluates Phase I Exploration Program
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 13
-
Battery X Metals Announces Closing of Second Tranche of Private Placement to Advance Corporate Growth Initiatives
-
3 Home Repairs You Can't Afford to Put Off
-
Grieving Messi available for Miami in Leagues Cup clash
-
Trump 'low-key' bets on economic pressure against Iran
-
Colombia enters 'final phase' of quake search as toll hits 265
-
Pitch invaders take selfies with Fernandes during Man Utd friendly
-
Father-figure Christie helps guide Kounta to European silver
-
No-stress Sabalenka won't fret over lackluster 2026 results
-
McIlroy returns to St. Jude to launch marathon PGA playoff push
-
Hometown hero Hudson-Smith basks in Euro glory
-
Guimaraes makes Arsenal debut in Como friendly
-
PSG down Aston Villa to retain UEFA Super Cup
-
Travis Kelce says wedding to Taylor Swift was 'best night of my life'
-
Trump's spokesperson Karoline Leavitt to step down
-
US stocks mostly up after data shows slightly lower inflation in July
-
'Imposing ignorance': US climate science under siege
-
Caracas protest denounces secrecy of Venezuela transition talks
-
As millions gazed in awe, a swathe of Spain plunged into darkness
-
Hudson-Smith regains Euro 400m title on home track
Coalition of states vows to protect access to abortion pill under Trump review
A coalition of attorneys general across states including New York, Minnesota and Arizona vowed Monday to protect access to mifepristone, the medication used in the majority of abortions in the United States.
The move comes as the Trump administration has reportedly launched a review into the medication's safety, in what many abortion rights' organizations have dubbed a blatant attempt to undermine health care access.
"The decision to reexamine access to this medication was made in response to a scientifically baseless letter and ignores decades of research that prove mifepristone is safe and effective," read the joint statement that included New York's Attorney General Letitia James, who co-led the coalition of 20 officials in the effort.
"Medical decisions should be left between patients, their families, and their providers – and they should be guided by science, not political agendas," the statement continued.
"If access to mifepristone is challenged, we will take action to protect it," it added.
Officials who co-signed the initiative represented Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, Washington state, and the District of Columbia.
Trump's health chief Robert F. Kennedy Jr and FDA Commissioner Marty Makary reportedly delivered a letter to 22 Republican attorneys general saying that the FDA was conducting its own review of the pill.
Proponents of reviewing mifepristone's safety have cited a study -- which was not peer-reviewed and published on a website, not in a scientific journal -- conducted by a conservative think-tank.
The Ethics & Public Policy Center (EPPC) says its priorities include "pushing back against the extreme progressive agenda while building a consensus for conservatives."
The medication has been used for 25 years in the United States. It is the most common method for abortion care and also routinely used for managing early miscarriage.
Mifepristone, which prevents pregnancy progression, and misoprostol, which empties the uterus, are approved to terminate a pregnancy up to 70 days of gestation in the United States.
A.Williams--AT